Trials (Aug 2020)

Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China

  • Xiaoke Li,
  • Ludan Zhang,
  • Mei Qiu,
  • Yi Huang,
  • Huanming Xiao,
  • Bingjiu Lu,
  • Yuyong Jiang,
  • Fuli Long,
  • Hui Lin,
  • Jinyu He,
  • Qikai Wu,
  • Mingxiang Zhang,
  • Li Wang,
  • Xiaoning Zhu,
  • Man Gong,
  • Xuehua Sun,
  • Jianguang Sun,
  • Fengxia Sun,
  • Wei Lu,
  • Weihua Xu,
  • Guang Chen,
  • Zhiguo Li,
  • Danan Gan,
  • Xianzhao Yang,
  • Hongbo Du,
  • Yong’an Ye

DOI
https://doi.org/10.1186/s13063-020-04417-9
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Nucleos(t)ide analogues (NAs) are the first-line option against chronic hepatitis B (CHB). NAs produce potent suppression of viral replication with a small chance of HBsAg seroclearance and a high risk of virological relapse after discontinuation. The combined therapy of NAs plus traditional Chinese medicine (TCM) is widely accepted and has been recognized as a prospective alternative approach in China. Based on preliminary works, this study was designed to observe the therapeutic effect of TCM plus entecavir (ETV) against HBeAg-positive chronic hepatitis B with respect to reducing the recurrence risk after NA withdrawal. Methods/design The study is a nationwide, multicenter, double-blind, randomized, placebo-controlled trial with a duration of 120 weeks. A total of 18 hospitals and 490 eligible Chinese HBeAg-positive CHB patients will be enrolled and randomly allocated into the experimental group and control group in a 1:1 ratio. Patients in the experimental group will be prescribed TCM formulae (Tiaogan-BuXu-Jiedu granules) plus ETV 0.5 mg per day for consolidation therapy for 96 weeks. Patients in the control group will be prescribed TCM granule placebo plus ETV 0.5 mg per day for the same course. After consolidation therapy, all patients will discontinue their trial drugs and be closely monitored over the next 24 weeks. Once clinical recurrence (CR) occurs, ETV treatment will be restarted. The primary outcome is the cumulative rate of CR at the end of this trial. Conclusion This study is the first of its kind to observe therapeutic effects with respect to reducing recurrence after NA withdrawals after unified integrative consolidation therapy in the CHB population. Trial registration Chinese Clinical Trial Registry No. ChiCTR1900021232 . Registered on February 2, 2019

Keywords